A startup originating from the University of Tokyo and the University of Tsukuba, possessing proprietary technology for selectively amplifying hematopoietic stem cells in vitro. It aims to realize next-generation regenerative medicine through cell and gene therapies for blood disorders and genetic diseases, as well as vascular regeneration technology.
BEL, Inc. is a deep-tech company specializing in materials science and surface engineering, focusing on the development and social implementation of advanced functional surfaces with antibacterial, antiviral, and anti-biofilm properties. The company integrates polymer science, additive manufacturing (3D printing), and surface microstructure control to create next-generation functional coatings for applications in medical devices, infrastructure, environmental systems, and marine environments. BEL actively promotes international collaboration with universities, research institutes, and industrial partners, aiming to advance materials innovation by integrating materials science with digital technologies such as data science and digital twin methodologies.
Aortic stenosis is a life-threatening condition in which the aortic valve becomes severely narrowed. With an aging population, the number of patients is expected to increase dramatically worldwide in the coming years. Although valve replacement has become widely adopted, many patients are either too frail to tolerate the procedure or lack access to specialized treatment centers. As a result, a significant treatment gap still remains. DIVE, the device we are developing, synchronizes balloon expansion with the heartbeat to gently open the narrowed aortic valve. Its key advantage is the minimal physical burden on the patient. Through this technology, we aim to provide a safe and accessible treatment option — and ultimately save as many lives as possible.
A startup engaged in the design, manufacturing, and sales of measurement devices using laser-plasma technology. It provides high-precision measurement and analysis solutions, enhancing efficiency and sophistication in research, development, and industrial applications.
For the 1.2 million patients with chronic heart failure in Japan, a wristwatch-type wearable device will be used to detect heart murmurs and changes in activity levels specific to heart failure and recommend that patients seek medical attention. After the consultation, doctors will adjust oral medication, ultimately reducing re-hospitalization due to worsening heart failure.
